At day 9 post-tumour implantation, mice were intracranially treated with either control adenovirus (Ad-CMV-Tom) or adenoviruses targeting TGF-β signaling activity (Ad-Smad6 or Ad-Smad7). Here, SMAD6 is linked to neoplasm.